Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.

The Journal of molecular diagnostics : JMD - 1 Nov 2015

Clynick Britt, Tabone Tania, Fuller Kathryn, Erber Wendy, Meehan Katie, Millward Michael, Wood Benjamin A, Harvey Nathan T

Abstract excerpt

In recent years, there has been increasing use of BRAF-inhibiting drugs for the treatment of various malignancies, including melanoma. However, these agents are associated with the development of other nonmelanoma skin lesions, in particular squamoproliferative lesions such as keratoacanthomas (KAs), squamous cell carcinomas, and BRAF inhibitor-associated verrucous keratoses. The molecular pathogenesis of these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Mutational Analysis

Share to HRAS gene

Share to STK11 gene

Share to Keratosis

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 26319365
DOI: 10.1016/j.jmoldx.2015.05.009

Genes

BRAF
HRAS
APC
FGFR3
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.PMID 26319365Read ↗

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Semantic proximity Read ↗

Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?Semantic proximity Read ↗

BRAF Immunohistochemical Studies of Pediatric Conjunctival Lesions.Semantic proximity Read ↗

Vemurafenib-associated keratoses with genetic heterogeneity of RAS.Semantic proximity Read ↗

HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features.Semantic proximity Read ↗

BRAF Mutation Status in Inflamed Juvenile Conjunctival Nevus, Primary Acquired Melanosis and Conjunctival Common Nevus.Semantic proximity Read ↗

Development of RET mutant cutaneous angiosarcoma during BRAF inhibitor therapy.Semantic proximity Read ↗

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Semantic proximity Read ↗

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.Semantic proximity Read ↗

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.Semantic proximity Read ↗

Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.Semantic proximity Read ↗

Mosaic Muir Torre Syndrome: Keratoacanthoma as a Piece of the Puzzle.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.